Octapharma USA Launches Co-Pay Assistance Program for Patients Receiving Octagam® 5% and Octagam® 10%

Eligible Patients Can Receive Financial Support for Co-Payments, Co-Insurance and Deductibles Without Regard for Ability to Pay

HOBOKEN, N.J. (January 26, 2017) – Octapharma USA today announced a new financial support program for the immunology disease patient community. The Octapharma Co-Pay Assistance Program is available to primary humoral immunodeficiency (PI) patients who are currently receiving Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation or have a prescription to begin therapy; and those age 18 or older with chronic immune thrombocytopenic purpura (ITP) who are currently receiving Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation or have a prescription to begin therapy.

The new program offers eligible patients a maximum of $5,000 in co-pay assistance each calendar year for co-pay, co-insurance and deductible expenses associated with their treatment without regard for their ability to pay. Patients must have third-party commercial insurance to participate in the program.

“We realize that patient out-of-pocket expenses associated with healthcare can sometimes be daunting, therefore, Octapharma has committed to support a program specifically designed to supplement these costs,” said Octapharma USA President Flemming Nielsen. “Octapharma is focused on creating support programs that adapt to meet patient needs and ensure continued access to therapies recommended by their medical providers. Coupled with ongoing educational programs, these efforts emphasize our strong belief that patient needs must always come first.”

To enroll in the Octapharma Co-Pay Assistance Program, eligible patients should contact the Octapharma Support Center at (800) 554-4440. The program is not available to patients who are covered under Medicaid, Medigap, Medicare, VA, DOD, TRICARE or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program. Participants must be U.S. residents.

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Please see full prescribing information for complete boxed warning.

- Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam® 5% and Octagam® 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use
of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

- Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of immune globulin intravenous (human) (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam® 5% and Octagam® 10% do not contain sucrose.

- For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam® 5% and Octagam® 10% at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

CONTRAINDICATIONS
Octagam® 5% is contraindicated for patients with anaphylactic or severe systemic reactions to human immunoglobulin; IgA deficient patients with antibodies against IgA and a history of hypersensitivity; and patients with acute hypersensitivity reaction to corn. Octagam® 10% is contraindicated for patients with a history of anaphylactic or severe systemic reactions to human immunoglobulin; and IgA deficient patients with antibodies against IgA and a history of hypersensitivity.

For more information and full prescribing information on Octagam® 5% and Octagam® 10%, please visit www.octagamus.net.

About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.

MEDIA CONTACT:
Fred Feiner
Yankee Public Relations
fred@yankeepr.com
908-425-4878

GAM10-0113: PPR

Octapharma USA, Inc. • 121 River Street, Suite 1201 • Hoboken, NJ 07030 • 201-604-1130 • www.octapharmausa.com